GDF-15 Biomarker Associations with Liver Steatosis and Fibrosis Over 6 Years

626 participants from a population-based cohort were analyzed over a 6-year period to evaluate the role of Growth Differentiation Factor 15 (GDF-15) in liver disease. The retrospective study by Nicole Anna Dietzel, last updated in March 2026, examined associations between GDF-15, alcohol intake, FIB-4 scores, and metabolic risk factors. Results suggest GDF-15 modulates hepatic steatosis and fibrosis, particularly in individuals with metabolic or lifestyle risk factors.

Use Cases

• Modeling the relationship between GDF-15 levels and liver stiffness based on FIB-4 scores.
• Investigating the interaction between alcohol intake and GDF-15 on fibrosis progression.
• Analyzing the modulating effect of GDF-15 on hepatic steatosis in the context of insulin resistance (HOMA-IR).
• Studying the neuro-metabolic-immunologic axis in liver disease using clinical cohort data.

Strengths

• Data from a cohort of 626 participants provides a substantive sample for analysis.
• Longitudinal design with a 6-year follow-up period for observing associations.
• Analysis includes multiple clinical factors: GDF-15, FIB-4, alcohol intake, and HOMA-IR.
• Results include specific beta coefficients and p-values (e.g., β = 0.47, p = 0.045) for key interactions.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying dataset is unknown, which may limit suitability assessment.
• The 1.5 MB file size suggests a small dataset, potentially limited to summary results or a data dictionary.

Provenance

Source

figshare, author Nicole Anna Dietzel.

Collection Method

Retrospective cohort study analyzing participants from a large population-based cohort.

Time Range

Study period spans 6 years (specific start/end years not provided).

Freshness

Last updated 2026-03-18 07:42:19